published meta-analysis   sensitivity analysis   studies

remdesivir in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsNIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04] 0.70[0.47; 1.04]NIH NIAID ACTT-1, 202010%1,059moderatenot evaluable deaths (time to event analysis only)detailed resultsNIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04] 0.70[0.47; 1.04]NIH NIAID ACTT-1, 202010%1,059moderatenot evaluable clinical improvementdetailed resultsNIH NIAID ACTT-1, 2020 1.32 [1.12; 1.55] 1.32[1.12; 1.55]NIH NIAID ACTT-1, 202010%1,059moderatenot evaluable serious adverse eventsdetailed resultsNIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] 0.72[0.54; 0.96]NIH NIAID ACTT-1, 202010%1,063moderatenot evaluable deep vein thrombosisdetailed resultsNIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.64[0.23; 1.81]NIH NIAID ACTT-1, 202010%1,063moderatenot evaluable elevated liver enzymesdetailed resultsNIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.67[0.38; 1.18]NIH NIAID ACTT-1, 202010%1,063moderatenot evaluable hyperbilirubinemiadetailed resultsNIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.84[0.30; 2.34]NIH NIAID ACTT-1, 202010%1,063moderatenot evaluable pulmonary embolismdetailed resultsNIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.96[0.19; 4.80]NIH NIAID ACTT-1, 202010%1,063moderatenot evaluable renal impairmentdetailed resultsNIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]NIH NIAID ACTT-1, 202010%1,063moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2021-01-20 13:31 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 510 - roots T: 290